8-K filing — Jade Biosciences, Inc. (JBIO)
Filed: 2026-08-10 AccNo: 0001193125-26-341229 Size: 241 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
Wedbush Maintains Outperform on Jade Biosciences, Raises Price Target to $47
Wedbush analyst Laura Chico maintains Jade Biosciences (NASDAQ:JBIO) with a Outperform and raises the price target from $45 to $47.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 11, 2026, 1:40 PM
- Checked
- Aug 11, 2026, 1:40 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Jade Biosciences Q2 EPS $(0.76) Misses $(0.64) Estimate
Jade Biosciences (NASDAQ:JBIO) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $(0.64) by 18.75 percent. This is a 11.63 percent increase over losses of $(0.86) per share
Read original at benzingaJade Biosciences Enters Exclusive Worldwide License Agreement With Paragon Therapeutics; To Pay Up To $22M In Milestone Payments To Paragon; To Pay Paragon Low To Mid-Single-Digit Percentage Royalties On Net Sales Of Licensed Products; Paragon Barred From New Campaigns Targeting Licensed Target For At Least Five Years
Read original at benzinga